Certara, Inc.
CERT
Updated: 24/09/2026, 15:04:00
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.
No summaries found.
- Share price
- $8.64
- Market cap
- $1.34B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Jon Resnick
- Employees
- 1,546
- IPO date
- 11/12/2020
- Beta
- 1.408
- Last dividend
- $0.00
- Day range
- $8.59 – $9.13
- 52-week range
- $4.45 – $13.88
- 1-day performance
- -2.15%
- 1-year performance
- 94.16%
- Current drawdown (1Y)
- -37.75%
- CIK
- 0001827090
- CUSIP
- 15687V109
- ISIN
- US15687V1098
- Created
- 07/12/2025, 03:15:06
- Last update
- 24/09/2026, 15:04:00
Track Certara, Inc. with an AI analyst
See which prediction-market events move CERT, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
GlobeNewsWire • STOCK • 09/06/2026, 15:50:00
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
PRNewsWire • STOCK • 08/06/2026, 14:02:00
Certara Outlines AI Push, Cost Cuts and New Growth Engines at Jefferies Conference
MarketBeat • STOCK • 07/06/2026, 16:02:50
Certara, Inc. (CERT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 03/06/2026, 21:31:58
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
GlobeNewsWire • STOCK • 02/06/2026, 18:33:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
GlobeNewsWire • STOCK • 26/05/2026, 18:54:00
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
GlobeNewsWire • STOCK • 24/05/2026, 16:14:00
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
GlobeNewsWire • STOCK • 22/05/2026, 21:00:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
PRNewsWire • STOCK • 21/05/2026, 20:40:00
Certara, Inc. (CERT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 19/05/2026, 19:40:51
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
GlobeNewsWire • STOCK • 18/05/2026, 21:00:00
Certara to Participate in Upcoming Investor Conferences
GlobeNewsWire • STOCK • 18/05/2026, 18:15:00